# Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

> **NCT01008527** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 22 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** CP 870,893
- **BIOLOGICAL:** Peptides
- **BIOLOGICAL:** Oncovir poly IC:LC

## Key facts

- **NCT ID:** NCT01008527
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-09
- **Final completion:** 2015-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-09-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01008527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01008527, "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01008527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*